Study | Study type | Sample size | Age (years, mean ± SD) | Type of antibiotic | Length of antibiotic therapy (days, mean ± SD) | NOS/JS |
---|---|---|---|---|---|---|
Henry E. Rice 2001 | RCT | IV/PO: 16 | 11.9 ± 3.9 | IV: Ampicillin & gentamicin sulfate & clindamycin/PO: amoxicillin-clavulanate | 10.1 ± 0.5 | 3 |
IV: 10 | 12.5 ± 3.7 | IV:Ampicillin & gentamicin sulfate & clindamycin | 10.4 ± 1.3 | |||
Obinna O. Adibe 2008 | OCS | IV/PO: 47 | 9.7 ± 0.52 | IV: Ampicillin–Sulbactam & Gentamicin OR Ampicillin–Sulbactam/PO: TMP-SMX & Metronidazole | 14 ± 0 | 8 |
IV:102 | 8.8 ± 0.41 | IV:Ampicillin–Sulbactam & Gentamicin OR Ampicillin–Sulbactam | 14 ± 0 | |||
Jason D. Fraser 2010 | RCT | IV/PO: 50 | 10.1 ± 4.6 | IV: Ceftriaxone & Metronidazole/PO: Amoxicillin-Clavulanate | ≥ 5 | 2 |
IV: 52 | 9.7 ± 4.2 | IV:Ceftriaxone & Metronidazole | 7 ± 0 | |||
Shannon N. Acker 2016 | OCS | IV/PO: 291 | 9.7 ± 4.1 | IV: Ceftriaxone & Metronidazole/PO: NA | NA | 8 |
IV: 34 | 8.9 ± 4.5 | IV:Ceftriaxone & Metronidazole followed by other types for home antibiotic | NA | |||
Tara J. Loux 2016 | OCS | IV/PO: 123 | 10.24 ± 4.3 | IV: Piperacillin-Tazobactam/PO: TMP-SMX & Metronidazole | 15.2 ± 8.4 | 7 |
IV: 98 | 10.51 ± 4.4 | IV:Piperacillin-Tazobactam followed by other types for home antibiotic | 15.2 ± 8.5 | |||
Michael R. Arnold 2018 | RCT | IV/PO: 38 | 10.1 ± 3.6 | IV: Ertapenem/PO: Amoxicillin-clavulanate | 10 ± 0 | 3 |
IV: 44 | 12.3 ± 3.6 | IV:Ertapenem | 10 ± 0 |